Business
Baxter Reports Fourth-Quarter 2025 Results
DEERFIELD, Ill., February 12, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025.
About this update from Baxter International Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2","length":131,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44","length":161,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Company advances ongoing board of directors refreshment","length":55,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":347,"olType":false},{"type":"text","content":"DEERFIELD, Ill., February 12, 2026--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025.","length":170,"tagName":"p"},{"type":"text","content":""While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said Andrew Hider, president and CEO. "We recently introduced a new operating model that is designed to simplify our organization, accelerate innovation and improve performance. These changes further decentralize the business and embed critical functional roles directly within each division – bringing us closer to our customers and ultimately helping us to improve our say-do ratio and execute more consistently. While the work ahead will take time, I’m encouraged by the dedication of our employees and remain confident in Baxter’s long-term trajectory."","length":788,"tagName":"p"},{"type":"text","content":"Fourth-Quarter 2025 Companywide Financial Results","length":49,"tagName":"p"},{"type":"text","content":"Note that continuing operations exclude Baxter’s Kidney Care business, which was acquired by Carlyle in January 2025, and is reported as discontinued operations.","length":161,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Worldwide sales from continuing operations in the fourth quarter totaled approximately $2.97 billion, increasing 8% on a reported basis and 3% on an operational basis.","length":167,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"U.S. sales from continuing op...